TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7857733

Group type: EXPERIMENTAL
Intervention: 2.5 mg ramipril
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 5 mg ramipril
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 2806622

Group type: EXPERIMENTAL
Intervention: Medium B (2% UltroSer G)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Medium A (10% human fetal cord serum)
Number of subjects: 141
Study: 785107

Group type: EXPERIMENTAL
Intervention: Intrapleural BCG vaccine administered in a single postoperative dose
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 38
Study: 31494545

Group type: EXPERIMENTAL
Intervention: Deterministic algorithms for maximum consensus estimation
Number of subjects: 0
Study: 31605198

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER) diet: 2600 kJ for two days/week.
Number of subjects: 197

Group type: COMPARATOR
Intervention: Continuous energy restriction (CER) diet: 2100 kJ/day below estimated requirements.
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Both IER and CER groups.
Number of subjects: 197
Study: 30876922

Group type: EXPERIMENTAL
Intervention: Dispatcher assistance (DA+)
Number of subjects: 412

Group type: COMPARATOR
Intervention: No dispatcher assistance (DA-)
Number of subjects: 412
Study: 28583140

Group type: EXPERIMENTAL
Intervention: Single fresh blastocyst transfer
Number of subjects: 4

Group type: COMPARATOR
Intervention: Single frozen blastocyst transfer
Number of subjects: 4
Study: 25833335

Group type: EXPERIMENTAL
Intervention: Telegenetics (via live videoconferencing)
Number of subjects: 162

Group type: COMPARATOR
Intervention: In-person CGC
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Telegenetics
Number of subjects: 162
Study: 24132976

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU vitamin D3, 2 times during the study)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 21896264

Group type: EXPERIMENTAL
Intervention: Six sessions of smoking cessation telephone support delivered by bilingual psychologists (n=213)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Usual care (n=194)
Number of subjects: 407
Study: 19675378

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 17668979

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD; 20 mg twice a day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 14705234

Group type: EXPERIMENTAL
Intervention: Tramadol 37.5 mg/acetaminophen 325 mg (tramadol/APAP)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 11145764

Group type: EXPERIMENTAL
Intervention: Biphasic waveform in group 1
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Biphasic waveform in group 2
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Monophasic waveform in group 1
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Monophasic waveform in group 2
Number of subjects: 118
Study: 9699102

Group type: EXPERIMENTAL
Intervention: Positive therapeutic suggestions during neurolept-anaesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Empty tape (control group)
Number of subjects: 100
Study: 7989521

Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotrophin (HMG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomiphene/HMG
Number of subjects: 0
Study: 2729930

Group type: EXPERIMENTAL
Intervention: Cefmetazole (2 g intravenously)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cefmetazole with probenecid pretreatment (1 g orally)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cefoxitin (2 g intravenously)
Number of subjects: 16
Study: 31277120

Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no eculizumab treatment)
Number of subjects: 17
Study: 28592294

Group type: EXPERIMENTAL
Intervention: Calf raising and walking exercise
Number of subjects: 28
Study: 26381229

Group type: EXPERIMENTAL
Intervention: output‐oriented individual intervention and articulation practice home program
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: output‐oriented individual intervention and dialogic reading home program
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: input‐oriented individual intervention and articulation practice home program
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: input‐oriented individual intervention and dialogic reading home program
Number of subjects: 65
Study: 23784010

Group type: EXPERIMENTAL
Intervention: BRCA Gist intelligent tutoring system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: National Cancer Institute (NCI) Web pages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22120032

Group type: EXPERIMENTAL
Intervention: Touch contact (TC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No contact (NC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Force contact (FC)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Functional Mobility (FM) scale
Number of subjects: 62
Study: 19784445

Group type: EXPERIMENTAL
Intervention: Insecticide-treated nets (ITNs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microbial larvicides
Number of subjects: 0
Study: 17130095

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Standard care alone (placebo)
Number of subjects: 1218
Study: 12627415

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open mesh surgery
Number of subjects: 0
Study: 12383810

Group type: EXPERIMENTAL
Intervention: Frequency-Doubling Technology (FDT) perimetry
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Swedish Interactive Threshold Algorithm (SITA) perimetry
Number of subjects: 276
Study: 9578182

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (400 ml)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8
Study: 7539183

Group type: EXPERIMENTAL
Intervention: Androgen withdrawal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 0
Study: 2533074

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg p.o.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg p.o.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 700249

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 gram per day for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31028041

Group type: EXPERIMENTAL
Intervention: High-flow oxygenation by nasal cannula (HFNC)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Face mask preoxygenation
Number of subjects: 186
Study: 28153353

Group type: EXPERIMENTAL
Intervention: Nebulised magnesium sulphate (1ml of 15% magnesium sulphate + 1.5ml isotonic saline) with nebulised salbutamol (0.15mg/kg/dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nebulised salbutamol (0.15mg/kg/dose) and 2.5ml isotonic saline (Placebo group)
Number of subjects: 100
Study: 25279787

Group type: EXPERIMENTAL
Intervention: High dose GQD (n=44)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Moderate dose GQD (n=52)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Low dose GQD (n=50)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 187
Study: 23586537

Group type: EXPERIMENTAL
Intervention: Group 'Different' trained on subsequences LLR, LRR, RLL, and RRL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 'Same' trained on subsequences LLL, LRL, RLR, and RRR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group trained on a pseudorandom ordering
Number of subjects: 0
Study: 21679506

Group type: EXPERIMENTAL
Intervention: Synthetic polyurethane foam (SPF)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 64
Study: 20058593

Group type: EXPERIMENTAL
Intervention: Tecnis ZM900 MIOL (multifocal group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Tecnis ZA9003 IOL (monofocal group)
Number of subjects: 114
Study: 17098754

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone-marrow-derived progenitor cells (BMCs)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo medium
Number of subjects: 204
Study: 15071126

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 741
Study: 11297577

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment for 18 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment for 18 months
Number of subjects: 40
Study: 9173675

Group type: EXPERIMENTAL
Intervention: Cerebrolysin infusion (20 ml in 500 ml Ringer) for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vitamin B infusion 5 ml vitamin B complex in 500 ml Ringer) for 10 days
Number of subjects: 20
Study: 8192292

Group type: EXPERIMENTAL
Intervention: Collaborative overviews of randomized trials
Number of subjects: 0
Study: 31518023

Group type: EXPERIMENTAL
Intervention: 250 g CSO per ton
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 500 g CSO per ton
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control (0 g CSO per ton)
Number of subjects: 162
Study: 29897573

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir + lamivudine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir + two NRTIs
Number of subjects: 92
Study: 27914488

Group type: EXPERIMENTAL
Intervention: 6-month dual antiplatelet therapy (DAPT)
Number of subjects: 2700

Group type: COMPARATOR
Intervention: 12 months or longer dual antiplatelet therapy (DAPT)
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 2700

Group type: COMPARATOR
Intervention: 12 months or longer DAPT
Number of subjects: 2700
Study: 24440364

Group type: EXPERIMENTAL
Intervention: Nonparetic arm force
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Contralesional to ipsilesional inhibition
Number of subjects: 9
Study: 22390572

Group type: EXPERIMENTAL
Intervention: Heparin 100 U/mL
Number of subjects: 214

Group type: COMPARATOR
Intervention: Saline flushes (control group)
Number of subjects: 214
Study: 20153794

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 85
Study: 18328639

Group type: EXPERIMENTAL
Intervention: Atomoxetine 90 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methylphenidate (90 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Phentermine (60 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Desipramine (100 and 200 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15914032

Group type: EXPERIMENTAL
Intervention: Stimulus duty cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus 'off' duration
Number of subjects: 0
Study: 12701941

Group type: EXPERIMENTAL
Intervention: Counseling (generic psychological therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antidepressants (routinely prescribed)
Number of subjects: 0
Study: 10586387

Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal (N = 18)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Gradual withdrawal (N = 20)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Continuation of caffeine level (N = 18)
Number of subjects: 57
Study: 8686349

Group type: EXPERIMENTAL
Intervention: Mesalazine (3 x 2 tablets of 250 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Olsalazine (2 x 2 capsules of 250 mg)
Number of subjects: 15
Study: 1906745

Group type: EXPERIMENTAL
Intervention: OKT3 therapy for immunosuppression
Number of subjects: 8
Study: 6196852

Group type: EXPERIMENTAL
Intervention: Urokinase 2,200 IU/kg/h
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Urokinase 1,100 IU/kg/h
Number of subjects: 33

Group type: COMPARATOR
Intervention: Streptokinase 100,000 IU/h
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 33
Study: 31852124

Group type: EXPERIMENTAL
Intervention: Light vegetarian diet (LVD)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Drug + diet group
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo + diet group
Number of subjects: 184

Group type: COMPARATOR
Intervention: Drug group
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 184
Study: 30027003

Group type: EXPERIMENTAL
Intervention: Cetirizine 10‐mg once daily in the morning (QAM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine 10‐mg once daily at bedtime (QHS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine 5‐mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine 5‐mg QAM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine 10‐mg QHS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 8‐mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine (all groups)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine (all groups in study 1)
Number of subjects: 0
Study: 26778151

Group type: EXPERIMENTAL
Intervention: HEMA contact lenses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SiHy contact lenses
Number of subjects: 30
Study: 25081694

Group type: EXPERIMENTAL
Intervention: Beta glucan (two 10-mg capsules daily for 21 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (two capsules daily for 21 days)
Number of subjects: 30
Study: 23137731

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 791
Study: 19434781

Group type: EXPERIMENTAL
Intervention: Emerging therapies targeting immune-mediated disease mechanisms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging therapies targeting distinct cell types and mechanisms
Number of subjects: 0
Study: 17845742

Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg PO
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg PO
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Ondansetron 4 mg IV
Number of subjects: 1599
Study: 14998579

Group type: EXPERIMENTAL
Intervention: Nimodipine tablets with pH 4.5 acetate buffer containing 0.05% sodium dodecyl sulfate (SDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nimodipine tablets with pH 4.5 acetate buffer containing 0.3% SDS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two brands of nimodipine tablets
Number of subjects: 0
Study: 11591558

Group type: EXPERIMENTAL
Intervention: Albuterol (10 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9498433

Group type: EXPERIMENTAL
Intervention: Zalcitabine (dideoxycytidine) monotherapy
Number of subjects: 38
Study: 7748646

Group type: EXPERIMENTAL
Intervention: Use of brief screening instruments for dementia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of brief screening instruments for depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of brief screening instruments for dementia and depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical judgement alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heavy drinking screening
Number of subjects: 0
Study: 2927306

Group type: EXPERIMENTAL
Intervention: Group A (limited ROM 120 degrees to 60 degrees of knee flexion)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Group B (limited ROM 60 degrees to 0 degrees of knee flexion)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Group AB (full ROM)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 59
Study: 30553026

Group type: EXPERIMENTAL
Intervention: Moderate exercise intensity group (MG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 34
Study: 26141208

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 165

Group type: COMPARATOR
Intervention: Chemotherapy (gemcitabine plus carboplatin)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sequential combination of EGFR-TKI and chemotherapy
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: No post-study treatments
Number of subjects: 165
Study: 23258572

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3445
Study: 20681813

Group type: EXPERIMENTAL
Intervention: Marginal periosteal pedicle (MPP) graft as an autogenous guided tissue membrane
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 15
Study: 19958868

Group type: EXPERIMENTAL
Intervention: XIENCE V
Number of subjects: 1002
Study: 16162829

Group type: EXPERIMENTAL
Intervention: Painful stimulus (sharp probe)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpainful stimulus (blunt probe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatially congruent position of rubber hand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spatially incongruent position of rubber hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational-affective coding areas (mid-cingulate BA24 and anterior insula)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Premotor areas
Number of subjects: 0
Study: 15478384

Group type: EXPERIMENTAL
Intervention: NebuChamber (200 microg of budesonide twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: AeroChamber (200 microg of budesonide twice daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NebuChamber
Number of subjects: 30

Group type: COMPARATOR
Intervention: AeroChamber
Number of subjects: 30
Study: 11137829

Group type: EXPERIMENTAL
Intervention: Nisoldipine 40 mg
Number of subjects: 646

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 646
Study: 9537937

Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin (INR 2 to 3)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR 1.2 to 1.5) plus aspirin (325 mg/d)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Combination therapy (low-intensity warfarin plus aspirin)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Complex aortic plaque
Number of subjects: 382
Study: 7841756

Group type: EXPERIMENTAL
Intervention: Naoxin Sutong (NXST)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ligustrazine (LT)
Number of subjects: 41
Study: 3372408

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive loading (RES)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sinusoidal pressure loading (SIN)
Number of subjects: 9
Study: 29649372

Group type: EXPERIMENTAL
Intervention: Autogenous bone grafts from mandibular symphysis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bovine bone graft associated with platelet-rich plasma (PRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bovine bone graft associated with PRP
Number of subjects: 20
Study: 29077990

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (three sessions weekly) plus compression therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Compression therapy only
Number of subjects: 39
Study: 26647766

Group type: EXPERIMENTAL
Intervention: Self-treatment group (STG)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 142
Study: 25017268

Group type: EXPERIMENTAL
Intervention: Intervention group (received explanatory pamphlet and letter to primary care physician)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no additional materials)
Number of subjects: 99
Study: 22129852

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (300 g/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional yogurt (300 g/d)
Number of subjects: 64
Study: 19900577

Group type: EXPERIMENTAL
Intervention: Video-based intervention (12-minute intervention video)
Number of subjects: 968

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 968
Study: 17442229

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor antagonists (ARA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensified blood pressure control and metabolic control in diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early intervention before progressive glomerulosclerosis
Number of subjects: 0
Study: 15536162

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily)
Number of subjects: 21
Study: 12221387

Group type: EXPERIMENTAL
Intervention: Professional oral health care (POHC)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Non-POHC
Number of subjects: 141
Study: 10721042

Group type: EXPERIMENTAL
Intervention: L-tryptophan 6 g per day
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 7593878

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine plus clinical management (IMI-CM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus clinical management (PLA-CM)
Number of subjects: 0
Study: 1691134

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytosine arabinoside (Ara-C) (1 g/m2 i.v. q 12 h days 1-6) and amsacrine (m-AMSA) (120 mg/m2 i.v. days 5-7)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High-dose Ara-C (3 g/m2 i.v. q 12 h days 1-4) and m-AMSA (120 mg/m2 i.v. day 5) for consolidation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 34
Study: 6154272

Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 232

Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 232